Abstract
Relebactam is a non-β-lactam, bicyclic diazabicyclooctane β-lactamase inhibitor of class A and class C β-lactamases, including Klebsiella pneumoniae carbapenemases (KPCs). It is in phase 3 clinical development in combination with imipenem/cilastatin. The in vitro activities of imipenem-relebactam, imipenem, and comparators were determined using the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method for isolates of Enterobacteriaceae (n = 3,419) and Pseudomonas aeruginosa (n = 896) collected in 2016 by 21 U.S. hospital laboratories participating in the SMART (Study for Monitoring Antimicrobial Resistance Trends) global surveillance program. Relebactam was tested at a fixed concentration of 4 μg/ml. Imipenem-relebactam MICs were interpreted using CLSI breakpoints for imipenem. Rates of susceptibility to imipenem-relebactam and imipenem for non-ProteeaeEnterobacteriaceae (n = 3,143) and P. aeruginosa were 99.1% (3,115/3,143) and 95.9% (3,013/3,143) and were 94.4% (846/896) and 74.7% (669/896), respectively. Relebactam restored imipenem susceptibility to 78.5% (102/130) of imipenem-nonsusceptible non-ProteeaeEnterobacteriaceae and to 78.0% (177/227) of imipenem-nonsusceptible P. aeruginosa isola...Continue Reading
References
Mar 1, 1988·Antimicrobial Agents and Chemotherapy·W J Brown
Aug 1, 1995·The Journal of Antimicrobial Chemotherapy·C NeuwirthA Kazmierczak
Sep 13, 2007·The Journal of Antimicrobial Chemotherapy·Mitchell J Schwaber, Yehuda Carmeli
May 21, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·O ZarkotouA Tsakris
Jul 29, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A-P MagiorakosD L Monnet
Dec 12, 2012·International Journal of Antimicrobial Agents·Karen BushDeidre Jarrett
Dec 12, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Dawn M SievertUNKNOWN National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities
May 23, 2013·The Journal of Antimicrobial Chemotherapy·David M LivermoreShazad Mushtaq
Nov 15, 2013·Advances in Nutrition·Shelley McGuire
Nov 30, 2013·Pharmaceuticals·Ian MorrisseyDouglas Biedenbach
Mar 25, 2014·The Journal of Antimicrobial Chemotherapy·L F MatasejeM R Mulvey
Nov 8, 2014·Journal of Clinical Microbiology·Twisha S Patel, Jerod L Nagel
Mar 7, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J M PogueD Marchaim
Apr 13, 2015·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I Olsen
May 28, 2015·Antimicrobial Agents and Chemotherapy·Amabel LapueblaJohn Quale
Mar 30, 2016·International Journal of Antimicrobial Agents·Sibylle H LobRobert E Badal
Oct 22, 2016·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Lindsey M WeinerDawn M Sievert
Dec 21, 2016·Antimicrobial Agents and Chemotherapy·Joshua T ThadenVance G Fowler
Mar 16, 2017·Diagnostic Microbiology and Infectious Disease·Sibylle H LobDaniel F Sahm
Mar 23, 2017·Antimicrobial Agents and Chemotherapy·Sibylle H LobDaniel F Sahm
Apr 6, 2017·The Journal of Antimicrobial Chemotherapy·Katie L HopkinsNeil Woodford
Jun 21, 2017·Antimicrobial Agents and Chemotherapy·Ghady HaidarM Hong Nguyen
Aug 23, 2017·Antimicrobial Agents and Chemotherapy·Helio S SaderRobert K Flamm
Sep 13, 2017·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·H WrightD L Paterson
Sep 30, 2017·The Journal of Antimicrobial Chemotherapy·David M LivermoreNeil Woodford
Apr 7, 2016·Canada Communicable Disease Report = Relevé Des Maladies Transmissibles Au Canada·G J GermanM R Mulvey
Citations
May 24, 2019·Journal of Clinical Microbiology·Tomefa E AsempaJoseph L Kuti
Aug 1, 2019·Pathogens and Disease·Brandon Kulengowski, David S Burgess
Jul 3, 2019·Antimicrobial Agents and Chemotherapy·Tomefa E AsempaJoseph L Kuti
Sep 11, 2019·Expert Opinion on Pharmacotherapy·Krisztina M Papp-Wallace
Feb 23, 2019·Scientific Reports·Eva HeinzRichard A Strugnell
Feb 16, 2020·Pharmacotherapy·Jordan R SmithKimberly C Claeys
Aug 30, 2019·Clinical Microbiology Reviews·Juan P HorcajadaSantiago Grau
Mar 29, 2019·Antimicrobial Agents and Chemotherapy·Laura PuzniakVikas Gupta
Feb 15, 2019·Frontiers in Microbiology·Chau-Chyun SheuPo-Ren Hsueh
May 16, 2019·The Journal of Antimicrobial Chemotherapy·Sibylle H LobDaniel F Sahm
May 23, 2019·Frontiers in Microbiology·Bassam El HafiGhassan M Matar
Oct 23, 2019·The Journal of Antimicrobial Chemotherapy·Eva Le RunJean-Luc Mainardi
Oct 22, 2020·Research : a Science Partner Journal·Zifang ShangWei Huang
Oct 4, 2020·Current Opinion in Infectious Diseases·Abigail K KoisJoseph L Kuti
Jul 28, 2020·Expert Opinion on Pharmacotherapy·Mohamad MoussaAthanasios Papatsoris
Dec 4, 2020·Infection and Drug Resistance·Toni A Campanella, Jason C Gallagher
Nov 13, 2020·Clinical Microbiology Reviews·Dafna YahavLeonard Leibovici
Jun 4, 2021·Diagnostic Microbiology and Infectious Disease·Sibylle H LobDaniel F Sahm
Aug 10, 2021·Antimicrobial Agents and Chemotherapy·Sam Horwich-ScholefieldMark Pandori
Oct 13, 2021·Current Opinion in Infectious Diseases·Matteo BassettiDaniele Roberto Giacobbe